Merck moved deeper into KRAS G12D with an exclusive global licensing deal with SciBrunch Therapeutics for a preclinical oral inhibitor, including a $400 million upfront payment. The agreement totals $2.13 billion in potential milestones across development and commercialization for multiple indications, underscoring Merck’s push to broaden oncology targets with mutation-specific small molecules.